Other News To Note
Monday, March 25, 2013
pSivida Corp., of Watertown, Mass., said licensee Alimera Sciences Inc., of Atlanta, disclosed plans to resubmit a new drug application for Iluvien (fluocinolone acetonide intravitreal implant) in diabetic macular edema (DME) by the end of March.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.